Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2004.05.063 on June 15 2004

Journal of Clinical Oncology, Vol 22, No 16 (August 15), 2004: pp. 3408-3419
© 2004 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benson, A. B.
Right arrow Articles by Haller, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benson, A. B., III
Right arrow Articles by Haller, D. G.
Related Articles
Right arrowRelated Article

ASCO SPECIAL ARTICLE

American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

Al B. Benson, III, Deborah Schrag, Mark R. Somerfield, Alfred M. Cohen, Alvaro T. Figueredo, Patrick J. Flynn, Monika K. Krzyzanowska, Jean Maroun, Pamela McAllister, Eric Van Cutsem, Melissa Brouwers, Manya Charette, Daniel G. Haller

From the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

PURPOSE: To address whether all medically fit patients with curatively resected stage II colon cancer should be offered adjuvant chemotherapy as part of routine clinical practice, to identify patients with poor prognosis characteristics, and to describe strategies for oncologists to use to discuss adjuvant chemotherapy in practice.

METHODS: An American Society of Clinical Oncology Panel, in collaboration with the Cancer Care Ontario Practice Guideline Initiative, reviewed pertinent information from the literature through May 2003.

RESULTS: A literature-based meta-analysis found no evidence of a statistically significant survival benefit of adjuvant chemotherapy for stage II patients.

RECOMMENDATIONS: The routine use of adjuvant chemotherapy for medically fit patients with stage II colon cancer is not recommended. However, there are populations of patients with stage II disease that could be considered for adjuvant therapy, including patients with inadequately sampled nodes, T4 lesions, perforation, or poorly differentiated histology.

CONCLUSION: Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer. Patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use of adjuvant chemotherapy, particularly for those patients with high-risk stage II disease. The ultimate clinical decision should be based on discussions with the patient about the nature of the evidence supporting treatment, the anticipated morbidity of treatment, the presence of high-risk prognostic features on individual prognosis, and patient preferences. Patients with stage II disease should be encouraged to participate in randomized trials.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Related Article

  • Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group
    Alvaro Figueredo, Manya L. Charette, Jean Maroun, Melissa C. Brouwers, and Lisa Zuraw
    JCO 2004 22: 3395-3407 [Abstract] [Full Text]


This article has been cited by other articles:


Home page
 JCOHome page
C. E. Desch, K. K. McNiff, E. C. Schneider, D. Schrag, J. McClure, E. Lepisto, M. S. Donaldson, K. L. Kahn, J. C. Weeks, C. Y. Ko, et al.
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures
J. Clin. Oncol., July 20, 2008; 26(21): 3631 - 3637.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Zlobec, L. M. Terracciano, and A. Lugli
Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes
Clin. Cancer Res., June 15, 2008; 14(12): 3792 - 3797.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Zlobec, K. Baker, L. M. Terracciano, and A. Lugli
RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis
Clin. Cancer Res., June 15, 2008; 14(12): 3798 - 3806.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. N. Schwartz
Management of early and advanced colorectal cancer: Therapeutic issues
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S8 - S14.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
I Zlobec and A Lugli
Prognostic and predictive factors in colorectal cancer
J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Weiser, R. G. Landmann, M. W. Kattan, M. Gonen, J. Shia, J. Chou, P. B. Paty, J. G. Guillem, L. K. Temple, D. Schrag, et al.
Individualized Prediction of Colon Cancer Recurrence Using a Nomogram
J. Clin. Oncol., January 20, 2008; 26(3): 380 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Rekhraj, O. Aziz, S. Prabhudesai, E. Zacharakis, F. Mohr, T. Athanasiou, A. Darzi, and P. Ziprin
Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis
Ann. Surg. Oncol., January 1, 2008; 15(1): 60 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Zlobec, K. Baker, P. Minoo, J. R. Jass, L. Terracciano, and A. Lugli
Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression
Clin. Cancer Res., January 1, 2008; 14(1): 143 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Benson III
New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease
Clin. Cancer Res., November 15, 2007; 13(22): 6913s - 6920s.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. Simunovic and N. N. Baxter
Lymph Node Counts in Colon Cancer Surgery: Lessons for Users of Quality Indicators
JAMA, November 14, 2007; 298(18): 2194 - 2195.
[Full Text] [PDF]

Home page
 JCOHome page
D. J. Sargent, S. Patiyil, G. Yothers, D. G. Haller, R. Gray, J. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, et al.
End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group
J. Clin. Oncol., October 10, 2007; 25(29): 4569 - 4574.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Sezeur, F.P. Chatelet, Ch. Cywiner, Cl. de Labriolle-Vaylet, C. Chastang, Cl. Billotey, M. Malafosse, D. Gallot, P. Betton, F. Montravers, et al.
Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging
Clin. Cancer Res., September 15, 2007; 13(18): 5592s - 5597s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Xu, F. Wang, M. Di, Q. Huang, M. Wang, H. Hu, Y. Jin, J. Dong, and M. Lai
Classification Based on the Combination of Molecular and Pathologic Predictors is Superior to Molecular Classification on Prognosis in Colorectal Carcinoma
Clin. Cancer Res., September 1, 2007; 13(17): 5082 - 5088.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
D. M. Iddings, E. A. Koda, S. S. Grewal, R. Parker, S. Saha, and A. Bilchik
Association of Angiogenesis Markers With Lymph Node Metastasis in Early Colorectal Cancer
Arch Surg, August 1, 2007; 142(8): 738 - 745.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Cascinu, A. Zaniboni, M. Scartozzi, and F. Meriggi
Molecular Biology for Stage II Colorectal Cancer: The Jury Is Still Out
J. Clin. Oncol., July 1, 2007; 25(19): 2861 - 2861.
[Full Text] [PDF]

Home page
 JCOHome page
P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al.
Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tsujino, I. Seshimo, H. Yamamoto, C. Y. Ngan, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, and M. Monden
Stromal Myofibroblasts Predict Disease Recurrence for Colorectal Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2082 - 2090.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
Ann. Onc., December 1, 2006; 17(12): 1810 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. Iddings, A. Ahmad, D. Elashoff, and A. Bilchik
The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-analysis
Ann. Surg. Oncol., November 1, 2006; 13(11): 1386 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. B. Benson III
New Approaches to the Adjuvant Therapy of Colon Cancer
Oncologist, October 1, 2006; 11(9): 973 - 980.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. C. Gatter, and A. L. Harris
Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway--A Report of the Tumour Angiogenesis Research Group
J. Clin. Oncol., September 10, 2006; 24(26): 4301 - 4308.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
S. L. Chen, D. M. Iddings, R. P. Scheri, and A. J. Bilchik
Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications
CA Cancer J Clin, September 1, 2006; 56(5): 292 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I Chau and D Cunningham
Adjuvant therapy in colon cancer--what, when and how?
Ann. Onc., September 1, 2006; 17(9): 1347 - 1359.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Johnson, G. A. Porter, R. Ricciardi, and N. N. Baxter
Increasing Negative Lymph Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer
J. Clin. Oncol., August 1, 2006; 24(22): 3570 - 3575.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. K. Monga and M. J. O'Connell
Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions
Ann. Surg. Oncol., August 1, 2006; 13(8): 1021 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. C. G. Martin
Adjuvant Treatment of Stage II Colon Cancer: Is There a True No-Chemotherapy Group?
Ann. Surg. Oncol., June 1, 2006; 13(6): 766 - 767.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. Andre, D. Sargent, J. Tabernero, M. O'Connell, M. Buyse, A. Sobrero, J.-L. Misset, C. Boni, and A. de Gramont
Current Issues in Adjuvant Treatment of Stage II Colon Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 887 - 898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini
Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. N. Polite, J. J. Dignam, and O. I. Olopade
Colorectal Cancer Model of Health Disparities: Understanding Mortality Differences in Minority Populations
J. Clin. Oncol., May 10, 2006; 24(14): 2179 - 2187.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ottaiano, R. Franco, A. Aiello Talamanca, G. Liguori, F. Tatangelo, P. Delrio, G. Nasti, E. Barletta, G. Facchini, B. Daniele, et al.
Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients.
Clin. Cancer Res., May 1, 2006; 12(9): 2795 - 2803.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
V. R. Adams
Evolving role of antineoplastic agents in colorectal cancer
Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S4 - S11.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Lloyd, C. M. McIver, S.-A. Stephenson, P. J. Hewett, N. Rieger, and J. E. Hardingham
Identification of Early-Stage Colorectal Cancer Patients at Risk of Relapse Post-Resection by Immunobead Reverse Transcription-PCR Analysis of Peritoneal Lavage Fluid for Malignant Cells
Clin. Cancer Res., January 15, 2006; 12(2): 417 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. C. Gatter, A. L. Harris, and for Tumour and Angiogenesis Research Group
Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer
Clin. Cancer Res., December 15, 2005; 11(24): 8653 - 8660.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Sargent, H. S. Wieand, D. G. Haller, R. Gray, J. K. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, G. Francini, et al.
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
J. Clin. Oncol., December 1, 2005; 23(34): 8664 - 8670.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
N Andre and W Schmiegel
CHEMORADIOTHERAPY FOR COLORECTAL CANCER
Gut, August 1, 2005; 54(8): 1194 - 1202.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Krajewska, H. Kim, C. Kim, H. Kang, K. Welsh, S.-i. Matsuzawa, M. Tsukamoto, R. G. Thomas, N. Assa-Munt, Z. Piao, et al.
Analysis of Apoptosis Protein Expression in Early-Stage Colorectal Cancer Suggests Opportunities for New Prognostic Biomarkers
Clin. Cancer Res., August 1, 2005; 11(15): 5451 - 5461.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Teraishi, S. Wu, L. Zhang, W. Guo, J. J. Davis, F. Dong, and B. Fang
Identification of a Novel Synthetic Thiazolidin Compound Capable of Inducing c-Jun NH2-Terminal Kinase-Dependent Apoptosis in Human Colon Cancer Cells
Cancer Res., July 15, 2005; 65(14): 6380 - 6387.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. Twelves, A. Wong, M. P. Nowacki, M. Abt, H. Burris III, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulias, et al.
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
N. Engl. J. Med., June 30, 2005; 352(26): 2696 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey and D. J. Sargent
FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer
J. Clin. Oncol., May 20, 2005; 23(15): 3311 - 3313.
[Full Text] [PDF]

Home page
 J Oncol PractHome page
Centers for Medicare & Medicaid Services: Off-Label Use of Colorectal Cancer Drugs Allowed in Select Clinical Trials
J. Oncol. Pract, May 1, 2005; 1(1): 12 - 14.
[Full Text] [PDF]

Home page
 The OncologistHome page
F. Muggia
Section Editor's Note
Oncologist, May 1, 2005; 10(5): 323 - 324.
[Full Text] [PDF]

Home page
 The OncologistHome page
L. Baddi and A. Benson III
Adjuvant Therapy in Stage II Colon Cancer: Current Approaches
Oncologist, May 1, 2005; 10(5): 325 - 331.
[Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Johnston
Stage II Colorectal Cancer: To Treat or not to Treat
Oncologist, May 1, 2005; 10(5): 332 - 334.
[Full Text] [PDF]

Home page
 Ann OncolHome page
I. Chau, A. R. Norman, D. Cunningham, D. Tait, P. J. Ross, T. Iveson, M. Hill, T. Hickish, F. Lofts, D. Jodrell, et al.
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer
Ann. Onc., April 1, 2005; 16(4): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Meyerhardt and R. J. Mayer
Systemic Therapy for Colorectal Cancer
N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487.
[Full Text] [PDF]

Home page
 JCOHome page
S. Popat, R. Hubner, and R.S. Houlston
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
J. Clin. Oncol., January 20, 2005; 23(3): 609 - 618.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Mandala, G. Ferretti, S. Barni, A. de Gramont, T. Andre, and T. Hickish
Oxaliplatin in Colon Cancer
N. Engl. J. Med., October 14, 2004; 351(16): 1691 - 1692.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online